Regulation of sodium/calcium homeostasis by BacNa v gene therapy rescues cardiac dysfunction in chronic heart failure

Read full text Summarise with VIRAT
Authors: Tianyu Wu, Yongwu Li, Robin M. Perelli, Yiu Yan Siu, Anna Tornatore, Josue Nataren Moran, Xixian Jiang, Sophia DeLuca, Donald M. Bers, Craig S. Henriquez, Andrew Paul Landstrom, Nenad Bursac
Cited by: 0
References: 73

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Despite continued progress, therapies to augment contractile function and prevent arrhythmias in patients with heart failure remain limited. Here, we present a two-pronged gene therapy approach that simultaneously augments peak Na + current and Ca 2+ transient amplitude in cardiomyocytes (CMs) to alleviate heart failure pathogenesis. Using in vitro engineered neonatal rat heart tissues, ex vivo adult mouse CMs, and in silico rabbit CMs, we show that expression of prokaryotic Na + channels (BacNa v ) dose-dependently enhances Ca 2+ transients and contractility of CMs by modulating Na + /Ca 2+ exchanger activity and increasing sarcoplasmic reticulum Ca 2+ stores. In mice, adeno-associated virus 9 (AAV9)–mediated BacNa v therapy rescues contractile deficit, prevents arrhythmias, and improves transcriptomic dysregulation in a pressure-overload induced model of chronic heart failure. We further establish the safety of long-term systemic delivery of AAV9-BacNa v in mice. Collectively, these studies support the translational promise of BacNa v gene delivery as an effective therapy for electrical and contractile dysfunction in heart failure.

Fields of Study & Subjects

Cardiac electrophysiology and arrhythmias Virus-based gene therapy research Cardiac pacing and defibrillation studies

Publication details

Journal / source
Science Advances
Volume
12
Issue
12
Pages
eady4551–eady4551
Publication date
20 March 2026
Language
EN